EICHORPublic-registry site landscape for NCT05031494, “A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers”, a Melanoma study sponsored by Eucure (Beijing) Biopharma Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05031494 (registry record) |
| Study title | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers |
| Official title | A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC) |
| Sponsor | Eucure (Beijing) Biopharma Co., Ltd |
| Condition(s) | Melanoma; Pancreatic Ductal Adenocarcinoma |
| Phase | PHASE2 |
| Listed sites | 2 |
| Site countries | United States, Australia |
Patient-friendly overview of this study: eichor.com/study/NCT05031494.
Eichor generates a preliminary site-risk snapshot for NCT05031494 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Melanoma trials
← Eichor home · All tracked trials · Melanoma studies · Weekly briefs
